stockrow
Friday 6 November 2026
Export BLLN’s income statement to Excel — free account
BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
109.74
2.65
−2.36%
Follow BLLN
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
84.32 | 116.21 | 94.12 | 1,320.00 |
+6 more quarters Free account |
P/S ratio |
11.52 | 14.01 | 10.23 | 4.26 | |
P/FCF ratio |
148.42 | 167.83 | 137.37 | 82.68 | |
P/Operating CF |
401.02 | 609.40 | 234.99 | 120.39 | |
P/B ratio |
9.37 | 10.37 | 7.17 | 2.71 | |
Price to Tangible BV |
9.37 | 10.37 | 7.17 | 2.71 | |
EV/Sales |
10.44 | 12.86 | 8.97 | 2.82 | |
EV/EBITDA |
82.00 | 91.91 | 66.14 | 30.82 | |
EV/Operating CF |
95.17 | 112.67 | 84.99 | 35.00 | |
EV/FCF |
134.48 | 154.04 | 120.43 | 54.78 | |
Quick Ratio |
10.72 | 11.19 | 10.47 | 11.21 | |
Current Ratio |
11.25 | 11.69 | 10.92 | 11.69 | |
Net Debt/EBITDA |
0.00 | (51.40) | (21.48) | (32.98) | |
Debt/Assets |
11.71% | 12.50% | 12.88% | 9.10% | |
Debt/Equity |
0.00 | 0.17 | 0.18 | 0.12 | |
Asset Turnover |
0.80 | 1.09 | 1.01 | 0.96 | |
Operating CF/Net income |
0.72 | 1.13 | 0.86 | 1.91 | |
Capex/Depreciation |
0.00 | (1.19) | (1.50) | (0.52) | |
Interest Coverage |
1,837.17 | 687.88 | 1,783.40 | 3,444.00 | |
Research and Development Expense of Revenue |
16.44% | 15.82% | 13.56% | 14.84% | |
Selling, General and Administrative Expense of Revenue |
45.46% | 49.60% | 42.97% | 45.83% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.89% | 7.51% | 6.01% | 6.59% | |
Graham Net Nets |
0.10 | 0.08 | 0.12 | 0.31 | |
Graham Number |
0.00 | 16.39 | 14.41 | 6.50 | |
Earnings Yield |
1.19% | 0.86% | 1.06% | 0.08% | |
Free Cash Flow Yield |
0.67% | 0.60% | 0.73% | 1.21% | |
Revenue per Share |
2.60 | 2.36 | 2.36 | 6.05 | |
Operating CF per Share |
0.27 | 0.20 | 0.34 | 0.68 | |
Capex per Share |
(0.08) | (0.09) | (0.10) | (0.10) | |
Free Cash Flow per Share |
0.18 | 0.11 | 0.24 | 0.58 | |
Cash per Share |
11.88 | 11.82 | 11.70 | 31.24 | |
Shareholders Equity per Share |
0.00 | 11.57 | 11.01 | 30.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 11.57 | 11.01 | 30.24 | |
Free Cash Flow |
8.60 | 5.09 | 10.96 | 9.26 | |
Working Capital |
621.46 | 595.65 | 566.98 | 512.60 | |
Capital Expenditures |
(3.95) | (4.05) | (4.47) | (1.54) | |
Net Current Asset Value |
488.15 | 458.49 | 429.03 | 408.01 | |
EV/EBIT |
102.01 | 118.01 | 87.88 | 53.72 | |
Capex to Sales |
0.03 | 0.04 | 0.04 | 0.02 | |
Price to Operating Income |
112.58 | 128.57 | 100.24 | 81.08 | |
| Other line items | |||||
Average Receivables |
61.46 | 49.80 | — | — | |
Average Payables |
9.02 | 8.25 | — | — | |
Average Inventory |
19.64 | 14.93 | — | — | |
Average Assets |
544.01 | 364.85 | 350.36 | 316.33 | |
Average Common Equity |
— | 142.58 | — | — |
Columns are period end dates · fundamentals updated 4 Nov 2026